CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control over editorial content. More information is available here »
In February 2020, Nurtec ODT (rimegepant) became the second oral CGRP receptor antagonist (gepant) to be approved for the acute treatment of migraine in adults. Rimegepant is formulated as a fast-acting orally disintegrating tablet (ODT), and its approval was supported by data including results of the Phase 3 Study 303 of rimegepant ODT, and additional clinical trials of rimegepant tablet including Study 301 and Study 302.
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
